Anodyne

Gabapentin
Gabapentin
Molecular structure via molpic based on CDK
[]
Enable javascript to view conformer structure via 3Dmol.js
Physical properties
[]
171.24 g/mol [1]
AppearanceWhite to off-white crystalline solid; crystals from ethanol/ether [1]
TasteBitter [1]
Melting point162-166 °C; also reported as 165-167 °C [1]
DecompositionHazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx). [1]
Solubility>25.7 [ug/mL] (The mean of the results at pH 7.4) [1]
-1.1 [1]
Structural Identifiers
[]
C9H17NO2 [1]
2-[1-(aminomethyl)cyclohexyl]acetic acid [1]
C1CCC(CC1)(CC(=O)O)CN [1]
InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12) [1]
InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N [1]
Dosing
[]
Elimination half-life5 - 7 hours

Gabapentin

Gabapentin (also known as Gabapentine, 1-(Aminomethyl)cyclohexaneacetic acid, Aclonium, Gabapetin, Gabapentinum, gabapentina, Gabapentino, Fanatrex, Gralise or Serada) is a substance of the gabapentinoid class.

Chemistry

Salts []

Gabapentin is typically found in the form of its hydrochloride and hydrobromide salts.

 []

Gabapentin is a achiral mixture

Experience reports []

Legal status []

  • Australia: Gabapentin is a S4 substance.[3]
  • Brazil: Gabapentin is a C1 substance.
  • Canada: Gabapentin is a prescription only substance.
  • United Kingdom: Gabapentin is a Class C substance.
  • United States: Gabapentin is a prescription only, schedule 5 in select states substance.

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 3446, Gabapentin. Accessed June 26, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/3446

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Gabapentin. UNII: 6CW7F3G59X. Global Substance Registration System. Accessed June 26, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6CW7F3G59X

  3. Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed June 26, 2025. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017